Search | Clinical Trials Finder

Conditions: Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
Interventions: ADI PEG20, Ifosfamide, Radiotherapy, Mesna; Drug · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Surgical Wound
Interventions: Fish Skin Graft (FSG), Wound Vacuum-Assisted Closure (VAC); Device
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Surgery-Complications
Interventions: Fish skin graft; Device
Lead sponsor: Kerecis Ltd.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Arlington, Virginia

Conditions: Lamellar Ichthyosis
Interventions: CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle; Drug
Lead sponsor: Mayne Pharma International Pty Ltd; Industry
Eligibility: 12 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 10
States / cities: San Diego, California • Aurora, Colorado • New Haven, Connecticut + 7 more

Conditions: Non-healing Wound
Interventions: Platelet Rich Plasma; Other
Lead sponsor: St Elizabeth Healthcare; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Edgewood, Kentucky

Conditions: Leukodystrophy, White Matter Disease, Leukoencephalopathies, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD Gene Mutation, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus Merzbacher Like Disease, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 12,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 23
States / cities: Los Angeles, California • Orange, California • Palo Alto, California + 18 more

Conditions: Wounds, Pressure Ulcer, Diabetic Foot Ulcer, Venous Leg Ulcer, Surgical Wound, Soft Tissue Reinforcement
Interventions: Kerecis Fish Skin Graft; Device
Lead sponsor: Kerecis Ltd.; Industry
Eligibility: Not listed
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 6
States / cities: Sarasota, Florida • Greensboro, North Carolina • Beavercreek, Ohio + 2 more

Conditions: Irritable Bowel Syndrome
Interventions: Rimegepant 75 MG [Nurtec]; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ichthyosis
Interventions: Imsidolimab, placebo; Drug · Biological
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 7
States / cities: Palo Alto, California • New Haven, Connecticut • Miami, Florida + 4 more

Conditions: Ichthyosis, Netherton Syndrome
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 1 Year to 60 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Chicago, Illinois • New York, New York

Conditions: Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
Interventions: no intervention; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Necrotizing Fasciitis
Interventions: Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT), Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT); Device · Other
Lead sponsor: Kerecis Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Skin Diseases
Interventions: Dupilumab; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 6 Months and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Epidermolytic Ichthyosis, Palmoplantar Keratoderma, Pachyonychia Congenita
Interventions: Erlotinib; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Netherton Syndrome
Interventions: QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID; Drug
Lead sponsor: Quoin Pharmaceuticals; Industry
Eligibility: 14 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more

Conditions: Leukodystrophy, White Matter Disease, 4H Syndrome, Adrenoleukodystrophy, AMN, ALD, ALD (Adrenoleukodystrophy), X-linked Adrenoleukodystrophy, X-ALD, Adrenomyeloneuropathy, Aicardi Goutieres Syndrome, AGS, Alexander Disease, Alexanders Leukodystrophy, AxD, ADLD, Canavan Disease, CTX, Cerebrotendinous Xanthomatoses, Krabbe Disease, GALC Deficiency, Globoid Leukodystrophy, TUBB4A-Related Leukodystrophy, H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum, HBSL, HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity, LBSL, Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder), Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation, ALSP, CSF1R Gene Mutation, HCC - Hypomyelination and Congenital Cataract, MLC1, Megalencephalic Leukoencephalopathy With Subcortical Cysts 1, MLD, Metachromatic Leukodystrophy, PMD, Pelizaeus-Merzbacher Disease, PLP1 Null Syndrome, PLP1 Gene Duplication &#X7C; Blood or Tissue &#X7C; Mutations, Pelizaeus-Merzbacher-Like Disease, 1, Peroxisomal Biogenesis Disorder, Zellweger Syndrome, Refsum Disease, Salla Disease, Sialic Storage Disease, Sjögren, Sjogren-Larsson Syndrome, Van Der Knapp Disease, Vanishing White Matter Disease, Charcot-Marie-Tooth, CMT, Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency, Allan-Herndon-Dudley Syndrome, Cadasil, Cockayne Syndrome, Multiple Sulfatase Deficiency, Gangliosidoses, GM2 Gangliosidosis, BPAN, Labrune Syndrome, LCC, Mucopolysaccharidoses, TBCK-Related Intellectual Disability Syndrome
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 18 Years
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Volunteer, Sjogren's Syndrome, Salivary Gland Disease
Interventions: Not listed
Lead sponsor: National Institute of Dental and Craniofacial Research (NIDCR); NIH
Eligibility: 4 Years to 100 Years
Enrollment: 1,150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gender Dysphoria, Adult
Interventions: Tubularized augmented peritoneal cap vaginoplasty, Biopsy; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 19 Years to 99 Years · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Irritable Bowel Syndrome
Interventions: Mindfulness based Stress Reduction Training (MBSR); Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Netherton Syndrome
Interventions: DS-2325a, Placebo; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Constipation-predominant Irritable Bowel Syndrome
Interventions: Sodium chenodeoxycholate (NaCDC), Placebo; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy Volunteers, Atopic Dermatitis, Netherton Syndrome
Interventions: BPR277 ointment (controlled application), Placebo (Vehicle), BPR277 ointment, BPR277; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: New Haven, Connecticut • St Louis, Missouri • Fargo, North Dakota

Conditions: Netherton Syndrome
Interventions: Pimecrolimus 1% Cream; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Netherton Syndrome
Interventions: ATR12-351; Drug
Lead sponsor: Azitra Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • New Haven, Connecticut

Search by objective public record fields.

Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Use of Fish Skin Graft (FSG) to Improve Wound Healing and Expedite Discharge at a County Safety-net Hospital

Kerecis Case Registry for SurgiBind : Soft Tissue Reinforcement

A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis

Kerecis Fish Skin Grafts With and Without Platelet Rich Plasma (PRP)

The Myelin Disorders Biorepository Project

Kerecis Real-World Fish Skin Graft Registry

Comparison of Rimegepant and Placebo for Pain in IBS

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

Defining the Skin and Blood Biomarkers of Ichthyosis

Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)

AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF

Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders

Epidermal Growth Factor Receptor Inhibition for Keratinopathies

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies

Characterization of Diseases With Salivary Gland Involvement

Gender Affirming Vaginoplasty With Tubularized Augmented Peritoneal Cap (TAPCap) Utilizing Fish Skin Xenograft (Kerecis™)

Neuroimaging and Biomarkers in Chronic Visceral Pain

A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy Subjects

Cheno Effect on Transit in Health and IBS-C

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome

Safety Study of Elidel (Pimecrolimus) 1% Cream to Treat Netherton Syndrome

Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome